By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agilis Biotherapeutics 



  New York    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Agilis Biotherapeutics And T-Top Clinical Research Co. Ltd. Enter Into An Agreement For The Development Of Gene Therapy Treatment Of AADC Deficiency 3/22/2016 10:50:55 AM
Agilis Biotherapeutics Sponsors Inaugural Angelman Syndrome Biomarker And Outcome Measures Meeting 3/14/2016 11:06:23 AM
Agilis Biotherapeutics And Waisman Biomanufacturing Enter Into Exclusive Manufacturing Agreement For Friedreich’s Ataxia Gene Therapy 2/18/2016 9:50:49 AM
Agilis Biotherapeutics And National Taiwan University Enter Into Worldwide, Exclusive License Agreement For The Gene Therapy Treatment Of AADC Deficiency 1/28/2016 9:42:41 AM
Agilis Biotherapeutics Names Former H. Lundbeck A/S (LUN.CO) Executive, Christopher J. Silber, MD, As Chief Medical Officer 1/25/2016 7:32:12 AM
Agilis Biotherapeutics Named As Top Company To Watch 11/19/2015 11:46:57 AM
Agilis Biotherapeutics Announces FDA Orphan Drug Designation For AGIL-AS For The Treatment Of Angelman Syndrome 11/4/2015 9:12:38 AM
Agilis Biotherapeutics And University of South Florida Enter Into Worldwide, Exclusive License Agreement For The Treatment Of Cognitive Disorders Using Reelin-Based Therapies 9/17/2015 10:47:29 AM
Agilis Biotherapeutics Appoints Arthur Tzianabos, Ph.D., To The Board Of Directors 9/10/2015 11:23:29 AM
Agilis Biotherapeutics And The University of South Florida Enter Into Worldwide, Exclusive License Agreement For Angelman Syndrome Gene Therapy 5/13/2015 11:18:11 AM
12
//-->